Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis

dc.contributor.authorZakhour, Johnny
dc.contributor.authorSharara, Sima Lynn
dc.contributor.authorHindy, Joya Rita
dc.contributor.authorHaddad, Sara F.
dc.contributor.authorKanj, Souha S.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Infectious Diseases
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:44:48Z
dc.date.available2025-01-24T11:44:48Z
dc.date.issued2022
dc.description.abstractPseudomonas aeruginosa is a pathogen often encountered in a healthcare setting. It has consistently ranked among the most frequent pathogens seen in nosocomial infections, particularly bloodstream and respiratory tract infections. Aside from having intrinsic resistance to many antibiotics, it rapidly acquires resistance to novel agents. Given the high mortality of pseudomonal infections generally, and pseudomonal sepsis particularly, and with the rise of resistant strains, treatment can be very challenging for the clinician. In this paper, we will review the latest evidence for the optimal treatment of P. aeruginosa sepsis caused by susceptible as well as multidrug-resistant strains including the difficult to treat pathogens. We will also discuss the mode of drug infusion, indications for combination therapy, along with the proper dosing and duration of treatment for various conditions with a brief discussion of the use of non-antimicrobial agents. © 2022 by the authors.
dc.identifier.doihttps://doi.org/10.3390/antibiotics11101432
dc.identifier.eid2-s2.0-85140454496
dc.identifier.urihttp://hdl.handle.net/10938/30496
dc.language.isoen
dc.publisherMDPI
dc.relation.ispartofAntibiotics
dc.sourceScopus
dc.subjectAntibiotics
dc.subjectAntimicrobial resistance
dc.subjectHospital-acquired infections
dc.subjectPseudomonas aeruginosa
dc.subjectSevere sepsis
dc.subjectAntibiotic agent
dc.subjectAvibactam plus ceftazidime
dc.subjectBacteriocin
dc.subjectCefiderocol
dc.subjectCeftolozane plus tazobactam
dc.subjectCilastatin sodium plus imipenem plus relebactam
dc.subjectColistin
dc.subjectFosfomycin
dc.subjectPlazomicin
dc.subjectVaccine
dc.subjectAntibiotic resistance
dc.subjectAntimicrobial therapy
dc.subjectArtificial ventilation
dc.subjectBacteremia
dc.subjectBacterial clearance
dc.subjectCarbapenem resistant pseudomonas aeruginosa
dc.subjectCarbapenemase producing enterobacteriaceae
dc.subjectDrug infusion
dc.subjectExtended spectrum beta lactamase producing enterobacteriaceae
dc.subjectHospital infection
dc.subjectHospital mortality
dc.subjectHospitalization
dc.subjectHuman
dc.subjectInfectious agent
dc.subjectInfusion rate
dc.subjectIntensive care unit
dc.subjectLength of stay
dc.subjectMinimum inhibitory concentration
dc.subjectPhage therapy
dc.subjectPharmacokinetic parameters
dc.subjectPhenotype
dc.subjectPseudomonas infection
dc.subjectPseudomonas pneumonia
dc.subjectQuorum sensing
dc.subjectReview
dc.subjectSepsis
dc.subjectTreatment duration
dc.titleAntimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2022-5507.pdf
Size:
971.79 KB
Format:
Adobe Portable Document Format